Callos Andrew, Executive Vice President and Chief Commercial Officer at Cytokinetics (CYTK), has been a steady seller of company stock over the past year, with no open-market purchases recorded in his SEC Form 4 filings. Across 50 transactions in the single holding, his total sales reached approximately $15.3 million, while his acquisition value stood at zero. The pattern is consistent: recurring option exercises paired with same-day open-market sales, a structure that suggests routine portfolio liquidation rather than opportunistic timing.
The most recent activity, spanning March through July 2026, shows a clear cadence of monthly sales. On July 30, 2026, Andrew sold shares worth $1.12 million after exercising options valued at $325,640. Similar paired transactions occurred on July 1 ($1.29 million sold, $348,900 exercised), June 1 ($1.11 million sold, $348,900 exercised), and May 1 ($1.03 million sold, $596,699 exercised). Additional standalone sales on May 5, April 30, and April 15 brought in $875,474, $948,900, and $491,783, respectively. The selling accelerated in March, with five separate open-market sales totaling roughly $1.69 million between March 5 and March 18, alongside a $348,900 option exercise.
Notably, Andrew received four zero-value grants on March 15, 2026, which are compensation awards rather than purchases. His recent 14 sales, all in CYTK, dwarf any buying activity, and the absence of any "P" coded transactions underscores a one-directional bias. The dollar values are substantial—individual sales frequently exceed $1 million—and the regularity of the monthly pattern suggests a pre-arranged selling schedule. For investors, the takeaway is straightforward: Andrew is monetizing equity awards, not adding to his position, a signal that may warrant attention but not alarm given the mechanical nature of the option-exercise-and-sell structure.
AI-assisted summary